A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/topiramate XR in Overweight Adults with Comorbidities/obesity

A phase 3, multicenter, randomized, double-blind, double-dummy, parallel-group, active-drug- and placebo-controlled clinical trial to assess the safety, efficacy and superiority of the new fixed-dose combination sibutramine IR/topyramat XR in weight reduction in overweight adults with comorbidity(ies) or obesity

Start Date01 Apr 2026

Sponsor / Collaborator

Eurofarma Laboratórios SA

IRCT201012275483N1

/ CompletedNot ApplicableIIT

The effect of low calorie diet with and without sibutramine on metabolic syndrome risk factors and sonographic findings in non alcoholic fatty liver

Start Date18 Apr 2010

Sponsor / Collaborator-

NCT01184560

/ CompletedNot ApplicableIIT

A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine

The purpose of this study, conducted academic Pilot research purposes, this is not clear as to permit. when orlistat to sibutramine merge if there are additional effects of BMI and group, which has an attribute that is greater for the combined effect is to analyze.
Study phase: Investigator-initiated clinical study (Pilot study)
Method of blinding: Double-blind
Control: Placebo-controlled
Assignment method: Randomization (Sibutramine monotherapy group: Orlistat and Sibutramine combination group = 1 : 1)
Studied disease: Obesity
Study population: Subjects eligible for inclusion/exclusion criteria
Dosing period: Total 18 weeks Run-in period (2 weeks), dosing period (12 weeks) and post-dosing observation period (4 weeks)

Start Date01 Feb 2010

Sponsor / Collaborator

Gachon University Gil Medical Center

100 Clinical Results associated with Sibutramine Hydrochloride

100 Translational Medicine associated with Sibutramine Hydrochloride

100 Patents (Medical) associated with Sibutramine Hydrochloride

1,125

Literatures (Medical) associated with Sibutramine Hydrochloride

01 Feb 2025·TALANTA

Portable unibody semi-flow injection voltammetric sensor for on-site screening of illegal additive sibutramine in food supplements

Article

Author: Soleh, Asamee ; Wangchuk, Sangay ; Promsuwan, Kiattisak ; Samoson, Kritsada ; Limbut, Warakorn ; Saichanapan, Jenjira ; Saisahas, Kasrin

In this study, a simple, portable, unibody semi-flow injection system was coupled with a screen-printed electrode (SFI/SPE) for the on-site electrochemical screening of sibutramine (SBM) in food supplements. The SFI was fabricated by laser engraving acrylic plastic and was attached to a modified SPE with double-sided adhesive tape. The SPE was modified with a nanocomposite of nitrogen-doped graphene nanoflakes and carbon nanotubes synthesized using hydrothermal and ultrasonic methods. The morphological structure and electrochemical properties of the nanocomposite were thoroughly investigated. The portable SFI-SPE sensing system was designed to be interfaced with a smartphone. Sample solutions can be continuously injected into the sensing system using a plastic syringe and SBM is determined by square wave anodic stripping voltammetry, controlled by means of a smartphone. The developed sensing system displayed linear ranges from 0.010 to 10 μg mL⁻¹ and 10-60 μg mL⁻¹ with an LOD of 0.0035 μg mL⁻¹. The sensor delivered a response in a short time and demonstrated not only good reproducibility (RSDs ranging from 2.9 % to 4.9 % (n = 10)) and excellent resistance to interference but also high accuracy. The developed sensor was utilized for the screening and quantification of SBM in food supplements but the system could be used in a wider range of electrochemical (bio) sensor applications in the future.

01 Jan 2025·TALANTA

Identification of fenfluramine adulteration in slimming foods using a highly sensitive immunoassay

Article

Author: Li, Zhaodong ; Wang, Yu ; Chen, Yanhong ; Pan, Kangliang ; Zhang, Shiwei ; Qian, Zhenjie ; Huang, Xin-an ; Liu, Zhiwei ; Raza, Sayed Haidar Abbas ; Chen, Jiahong ; Yu, Xiaoqin ; Abbas Raza, Sayed Haidar ; Zhenjie, Qian ; Lei, Hongtao ; Huang, Xin-An

Fenfluramine, an appetite suppressant used for weight loss, can cause significant harm if overdosed. The unauthorized addition of fenfluramine to slimming foods has raised concerns. Currently, no rapid screening method is available for the quick detection of fenfluramine in the field. This study proposes six new haptens with varying spacer arm lengths and hydrophobicity, promising to elicit antibodies capable of being highly specific and strongly binding to fenfluramine. The study found that highly hydrophobic haptens with long spacer arms favored the generation of highly sensitive antibodies. Key interaction forces for antibody recognition of fenfluramine were revealed by intrinsic molecular mechanisms. Based on the above results, monoclonal antibody for fenfluramine was prepared and an ultrasensitive icELISA method with heterologous coating strategies was developed in slimming foods. The IC₅₀ of the method was 6.25 ng/mL, the linear detection range was 0.47-83.51 ng/mL and the detection limit was 0.10 ng/mL. Recovery rates in tea bags, tablets, capsules, coffee, and beverages ranged from 96.56 % to 108.90 %. The method was successfully applied to blind samples, showing strong correlation with HPLC-MS/MS results. Thus, the developed method is suitable for identifying fenfluramine adulteration in slimming foods.

01 Dec 2024·Forensic Chemistry

Application of GC–MS retention index in forensic routine

Author: e Ferreira, Luisa Pereira ; Machado, Yuri ; Ferrari, Ettore Junior ; Lordeiro, Rogerio Araujo

Gas chromatog.-mass spectrometry (GC-MS) is widely used for the identification of substances of forensic interest, but it faces challenges due to the vast diversity of available drugs.In this context, the use of the linear retention index (LRI) can help overcome difficulties associated with the identification of a large number of substances, as it is less susceptible to variations in exptl. conditions compared to retention time (RT).Building an LRI database allows rapid and simultaneous identification of several compounds, including new and structurally similar substances, thus standardizing anal. identification.This study aimed to evaluate the use of the retention index (RI) in both intralab. and interlaboratory forensic routines.Over a 50-wk period on the same GC-MS system, RI values were effectively adjusted by reinjecting an n-alkane mix after maintenance that required vacuum breaks, updating the retention times of each substance evaluated (benzocaine, caffeine, cocaine and flunitrazepam).Interlaboratory reproducibility was evaluated between two forensic laboratories using up to 104 analytes.Two oven temperature programs, three GC brands and two anal. columns were evaluated.Under the same anal. conditions, the ΔRI was ≤10 index units (i.u.) for 103 substances, with testosterone enanthate showing a ΔRI = 11 i.u..The proposed method proved to be reproducible and selective, and the use of RI has demonstrated accuracy as a complementary technique for identifying a wide range of analytes.Furthermore, the sharing of an RI database can strengthen the anal. routine, being a way to quickly obtain information on the identification of new drugs.

News (Medical) associated with Sibutramine Hydrochloride

24 Sep 2024

·www.biospace.com

Deep Dive: Obesity and Diabetes Markets Explode

A scale and fat cells Taylor Tieden for BioSpace In this deep dive BioSpace dissects the global obesity and diabetes markets along with the growing pipelines that aim to serve them. The global obesity market is forecasted to reach between $100 billion and $160 billion in the next decade. Meanwhile, the market for type 2 diabetes, which is closely related, is predicted to exceed $70 billion by 2032. There is thus considerable opportunity for Novo Nordisk, Eli Lilly, Pfizer and the multitude of other biopharma companies vying for a piece of the lucrative pie. Weight-Loss Market Estimates and Projections Source: IQVIA, Reuters, Goldman Sachs Taylor Tieden for BioSpace While exceedingly successful, many suspect the current GLP-1 injection therapies for obesity will ultimately be replaced by oral GLP-1 drugs, and several companies, including Lilly, Novo and Pfizer, are racing to bring their versions to the market. In addition, the space is not limiting itself to GLP-1s but is also exploring novel mechanisms to tackle these widespread diseases. Here, BioSpace examines the current obesity and diabetes markets along with the growing pipelines that aim to serve them. Weight Loss: A Two-Horse Race The obesity market is currently dominated by two companies: Novo Nordisk and Eli Lilly. While Novo’s obesity drug Wegovy had a two-year head start on Lilly’s Zepbound, the latter is making up ground . On August 7, Novo reported its second-quarter earnings , revealing profits of $1.7 billion for Wegovy and $4.23 billion for diabetes drug Ozempic. Despite growth rates of 53% and 30%, respectively, for the drugs, investors were not impressed because analyst forecasts were missed. Lilly, on the other hand, beat Q2 expectations , bringing in $1.24 billion for Zepbound and $3.1 billion for diabetes treatment Mounjaro. But the future is much more than a two-horse race. Several companies, including Pfizer , Roche , Viking Therapeutics , and Rivus Pharmaceuticals, are developing obesity therapeutics. Some leverage the GLP-1 pathway, while others commit to different mechanisms, including amylin analogs and mitochondrial uncoupling. Other players in the space include Veru Pharmaceuticals, Regeneron, Altimmune, Amgen, and Amylyx. Approval Timeline The obesity space truly caught fire with the clinical success of Wegovy and Zepbound, but these products follow several other treatments for obesity and diabetes approved over the past two-plus decades. Here is a sampling of noteworthy products. November 2023 Eli Lilly, Zepbound Generic name: Tirzepatide Treatment: Weight management June 2022 Vivus, Qsymia Generic names: Phentermine and topiramate Treatment: Weight management in pediatric patients May 2022 Eli Lilly, Mounjaro Generic name: Tirzepatide Treatment: Type 2 diabetes June 2021 Novo Nordisk, Wegovy Generic name: Semaglutide Treatment: Obesity December 2020 Novo Nordisk, Saxenda Generic name: Liraglutide Treatment: Obesity in adolescents September 2019 Novo Nordisk, Rybelsus Generic name: Semaglutide Treatment: Type 2 diabetes (pill form) December 2017 Novo Nordisk, Ozempic Generic Name: semaglutide Treatment: Type 2 diabetes September 2014 Takeda, Contrave Generic names: Naltrexone and bupropion Treatment: Weight loss July 2012 Vivus, Qsymia Generic names: Phentermine and topiramate Treatment: Weight management in adult patients January 2010 Novo Nordisk, Victoza Generic name: Liraglutide Treatment: Type 2 diabetes April 2005 Amylin Pharmaceuticals, Byetta Generic name: Exenatide Treatment: Type 2 diabetes The Highly Sought Weight-Loss Pill In 2019, the FDA approved Novo’s Rybelsus as the first oral GLP-1 for type 2 diabetes. Considered by many to be the next frontier in obesity treatment, oral medicines are under development by a number of companies, including Novo, whose amycretin is in Phase I trials, and Lilly, which has a Phase III trial underway for orforglipron. Brazilian owned multinational company Eurofarma also has a Phase III study underway for its oral candidate sibutramine/topiramate XR. Meanwhile, a host of companies have oral assets in earlier-stage trials. Pfizer recently announced that it would move forward with a modified-release formulation of its candidate danuglipron, and in December 2023, San Francisco–based Structure Therapeutics announced positive results from a Phase IIa trial of its weight-loss pill GSBR-1290. Note: Not all companies with oral medicines in Phase I and II trials are included. Taylor Tieden for BioSpace Widely hailed as “the next big thing” in the obesity space, several companies—including Eli Lilly, Novo Nordisk and Pfizer—are developing oral GLP-1 candidates. How long before oral GLP-1s take majority share of the market? Source: BioSpace LinkedIn poll , August 2024 Taylor Tieden for BioSpace This deep dive was originally published as a special edition of ClinicaSpace. Subscribe here .

Phase 2Clinical ResultPhase 3Phase 1Drug Approval

21 Jul 2023

·www.drugs.com

AHA News: Warnings – And Hope – From New Heart Disease Treatment Guidelines

THURSDAY, July 20, 2023 (American Heart Association News) -- New guidelines detailing how to care for people with heart disease come with some easy-to-grasp warnings for patients. The chronic coronary disease guidelines from the American Heart Association and American College of Cardiology, published Thursday in the AHA journal Circulation, are no incremental update, said Dr. Salim Virani, chairperson of the expert panel that rewrote them. "It's actually a new guideline in that everything that needed to be evaluated in terms of evidence was reviewed, and all the recommendations were rewritten," said Virani, vice provost of research and a professor of medicine at Aga Khan University in Karachi, Pakistan. Coronary disease includes various conditions that trace back to the buildup of plaque in artery walls that limits blood flow to the heart. That includes coronary artery disease , angina, heart attack and care after a procedure to open a blocked heart artery. The guidelines cover topics ranging from exercise to cholesterol management to bypass surgery. "This is pulling everything together as a one-stop shop for providers who take care of these kinds of patients," said Dr. Kristin Newby, the writing panel's vice chairperson. From that "one-stop shop," here are six warnings for people with coronary disease – plus an overall message to embrace. Avoid trans fat "Trans fats aren't good for anybody," said Newby, a professor of medicine and cardiology at Duke University in Durham, North Carolina. But people with coronary disease need to be extra careful. Of all the fats and oils used in cooking, Newby said, trans fats are the most likely to cause plaque in the arteries. In people with existing disease, trans fat has been linked to higher risk of heart attack and stroke, higher death rates from those problems, and a higher risk of premature death. Artificial trans fats are liquid oils that have been turned into a solid. Margarine and shortening are common examples. The Food and Drug Administration has banned food manufacturers from using a once-common source of trans fat: partially hydrogenated vegetable oils. But in some places, trans fats still show up in restaurant deep-fat fryers and elsewhere. Trans fats also occur naturally in beef, lamb and butterfat, but the guidelines say these pose less risk than artificial trans fats. Companies are allowed to say a food is free of trans fats even if they have as much as half a gram. To avoid trans fats, check nutrition labels and skip fried food, processed baked goods and refrigerated dough. And look for terms such as "partially hydrogenated oils" in the ingredients list. Beware of secondhand smoke Smoking is a well-known cause of heart disease. But even if you're not smoking, you need to be careful. "Every effort should be made to avoid secondhand smoke, because it carries many of the same chemicals and irritants that we think lead to coronary disease," Newby said. It's a matter of accumulating risk, Virani said. "If you have heart disease, and then you add secondhand smoke on top of everything else that's going on, the risk really goes up." For people who have had a heart attack, that includes a higher risk of having another one. Avoiding secondhand smoke can be tough if you work at a place where smoking is allowed. But if you have a family member who smokes, Virani said, "at a minimum" you should ask them to smoke outside. Be careful with common drugs, including ibuprofen "A lot of times we all have this misperception that if something is available over the counter, it is safe," Virani said. "Patients who have heart disease should be very mindful, even if it's vitamins." The guidelines offer a specific warning about nonsteroidal anti-inflammatory drugs, also known as NSAIDs. These drugs include ibuprofen and naproxen sodium. "What we're talking about here is not kind of a one-time use because your muscles are sore after working out," Newby said. "What we're talking about is using them every day." NSAIDs pose two issues for people with coronary disease, Virani said. First, extended use has been linked to cardiovascular problems, including having a second heart attack. Second, NSAIDs can cause bleeding in the stomach and intestines. A heart patient may be on one or even two blood-thinning medications, Virani said. Combine those with NSAIDs, and "your risk of bleeding goes up tremendously." Occasional use is not a problem, he said. But he and Newby recommend acetaminophen as an alternative. Don't combine erectile dysfunction drugs with nitrates Nitrates – including nitroglycerin – are prescribed for angina, or chest pain. Phosphodiesterase type 5 inhibitors – including sildenafil and tadalafil – are used for erectile dysfunction. Mixing them can cause a potentially life-threatening drop in blood pressure. "It's not about not using them," Newby said. "It's just about being careful." Tadalafil, for example, can stay in the system up to 48 hours, and some nitrates are long-acting as well. Men should talk to their doctor about how long the drugs last in the system, and look for alternatives if necessary, the experts said. Don't use these weight loss drugs Sympathomimetic weight loss drugs such as phentermine and benzphetamine work by suppressing appetite. They also raise your heart rate and blood pressure, which can strain a heart already suffering from compromised blood flow, Virani said. The drugs might lead to irregular heartbeats as well, he said. One drug in this class, sibutramine, was taken off the U.S. market in 2010 but might be available outside the country or sold illegally. Avoid them all, Virani said. "We have much, much better and safer weight loss medications." Be careful with postmenopausal hormone therapy Estrogen and progestin are given to women to help with postmenopausal symptoms such as hot flashes. In the context of heart disease, it has issues. First, Newby said, although hormones have been extensively studied in hopes of showing they protect against heart disease, intensive research found no benefit. But hormone therapy does raise the risk of venous thromboembolism, a blood clot in a deep vein or a lung. "What we are suggesting to patients with chronic coronary disease is to actually have that conversation with their treating clinician to see what other alternatives exist," Virani said. Given their already-elevated risk, "they've got to be very careful." And now the good news … Managing chronic coronary disease can seem like a list of limitations. Virani said it should also be seen as a wealth of opportunities. "You know, 30 to 40 years ago, having chronic coronary disease was really just like, 'OK, you're just going to have another heart attack one of these days, and you may or may not survive,'" he said. But even in the past four to five years, new treatments have made it more manageable than ever if people work with their health care professionals and take their medications. "So, there's a lot of hope as well," he said. "It's not a death sentence anymore. You can have a pretty normal life span and good quality of life if you actually follow the recommendations." American Heart Association News covers heart and brain health. Not all views expressed in this story reflect the official position of the American Heart Association. Copyright is owned or held by the American Heart Association, Inc., and all rights are reserved. By Michael Merschel, American Heart Association News Posted July 2023

AHA

20 Dec 2022

·www.prnewswire.com

DelveInsight Estimates a Promising Picture of Obesity Pipeline Space Landscape as Key 100+ Pharma Companies Working in the Space

The prevalence of obesity has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Obesity and the growing research and development activities to develop novel therapies to treat obesity drive the market. The Companies developing the potential therapies in the last stage of development include Novo Nordisk, Eli Lilly and Company, Saniona, and several others. LAS VEGAS, Dec. 20, 2022 /PRNewswire/ -- DelveInsight's ' Obesity Pipeline Insight – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline obesity therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the obesity pipeline domain. Key Takeaways from the Obesity Pipeline Report DelveInsight's obesity pipeline report depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for obesity treatment. Key obesity companies such as 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others are evaluating new drugs for obesity to improve the treatment landscape. Promising obesity pipeline therapies in various stages of development include Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others. In December 2022, Amgen announced new Phase I data from AMG 133. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes (NCT04478708). The MAD cohorts showed mean percent changes in body weight (BW), ranging from -7.2% at the lowest dose (140mg Q4W), to -14.5% at the highest dose (420mg Q4W) by day 85. A substantial degree of weight loss was maintained beyond the treatment period, which will be shared as part of the oral presentation. Most treatment-emergent adverse events (TEAEs) were mild and transient. The majority of the TEAEs were GI-related, with the most common being nausea and vomiting, most events resolved within 48 hours. In December 2022, Poolbeg Pharma, a clinical-stage infectious disease company, acquired the exclusive license from InsuCaps to use its proprietary microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes, and diabetes. In November 2022, Rhythm Pharmaceuticals, Inc. announced that Great Britain's Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age and older. In November 2022, Reviva Pharmaceuticals Holdings, Inc. announced the issuance of a patent covering the composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives and the use of the compositions for the treatment of obesity, related co-morbid conditions, and depression and related co-morbid conditions. In October 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity or overweight with weight-related comorbidities. In September 2022, Rivus Pharmaceuticals Inc. announced the completion of a USD 132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG, and existing investors Longitude Capital, Medicxi, and RxCapital. This financing will further support the clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease. In June 2022, LG Chem's new drug for treating genetic obesity received additional ODD (Orphan Drug Designation) from the US FDA. LG Chem announced on the 16th that the FDA recently granted ODD to ' LB54640' for the treatment of 'POMC (Proopiomelanocortin) deficiency.' In April 2022, Saniona announced that it paused the Phase IIb clinical trials testing Tesomet for people with Prader–Willi syndrome (PWS) and hypothalamic obesity (HO). The decision "is not related to the safety or efficacy of Tesomet and is entirely due to funding limitations. The company also announced a reprioritization and restructuring effort to immediately reduce operating expenses while maximizing cash resources. Request a sample and discover the recent advances in obesity drug treatment @ Obesity Pipeline Report The obesity pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage obesity drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the obesity clinical trial landscape. Obesity Overview Obesity is a chronic disease that causes abnormal or excessive fat accumulation or adipose tissue in the body, posing a health risk. It is caused by an imbalance between calories consumed and calories burned. The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain medications, and endocrine issues. Changes in the environment or society, as well as in behavior and culture, all directly impact. Obesity symptoms go beyond an increase in body fat. It can cause skin issues, shortness of breath, sleeping difficulties, and other symptoms. Some obesity symptoms have even been linked to an increased risk of developing certain diseases and disorders. In some cases, these can be life-threatening or even fatal. Find out more about drugs for obesity @ FDA-approved Obesity Drugs A snapshot of the Obesity Pipeline Drugs mentioned in the report: Learn more about the emerging obesity pipeline therapies @ Obesity Clinical Trials Obesity Therapeutics Assessment The obesity pipeline report proffers an integral view of obesity emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Obesity Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Glucagon like peptide 1 receptor agonists, Gastric inhibitory polypeptide receptor agonists, Beta 1 adrenergic receptor antagonists, Biogenic monoamine uptake inhibitors, Lipolysis modulators, Alpha-glucosidase inhibitors, Amylase inhibitors, Lipase inhibitors, Glucagon like peptide 1 receptor agonists, Glucagon receptor agonists, Islet amyloid polypeptide replacements Key Obesity Companies: 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others. Key Obesity Pipeline Therapies: Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others. Dive deep into rich insights for new drug for obesity treatment; visit @ Obesity Medications Table of Contents For further information on the obesity pipeline therapeutics, reach out @ Obesity Drug Treatment Related Reports Obesity Epidemiology Forecast Obesity Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the obesity epidemiology trends. Obesity Market Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, among others. Hypothalamic Obesity Market Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others. Hypothalamic Obesity Pipeline Hypothalamic Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others. HET Obesity/POMC Deficiency Obesity Pipeline HET Obesity/POMC Deficiency Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others. HET Obesity/POMC Deficiency Obesity Market HET Obesity/POMC Deficiency Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others. Other Trending Reports Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market Related Healthcare Blogs Obesity: A Global Concern Weight Loss and Obesity Market Obesity Treatment Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Phase 1Orphan DrugFast TrackPhase 2License out/in

100 Deals associated with Sibutramine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02571	Sibutramine Hydrochloride	A08AA10	DB01105

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	United States	Abbott Laboratories	22 Nov 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	United States	Abbott Laboratories	01 Jan 2003
Binge-Eating Disorder	Phase 3	-	Abbott Laboratories	01 Aug 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Not Applicable	Hemolysis	-	Biliverdin Reductase B (hG6PD(A-) mice)	mzhffgozyj(fiacqhuhal) = fdltvdacaz ipwcnsxjpt (oebckvqgdq )	-	10 Dec 2023
ESMO2020	Not Applicable	Transitional Cell Carcinoma	-	ribonucleotide reductase subunit family M1/M2 (High RRM1 expression)	qwlxzrzzxa(arfcedyvab) = txgmiiboty bctlofaluw (djtaxnzgtw )	-	17 Sep 2020
				ribonucleotide reductase subunit family M1/M2 (High RRM2 expression)	qwlxzrzzxa(arfcedyvab) = zztumuwjtv bctlofaluw (djtaxnzgtw )
ARVO2016	Not Applicable	Capsule Opacification alpha smooth muscle actin (α-SMA) \| vimentin (VIM) \| fibronectin (FN)	-	aldose reductase (Wild-type C57BL/6 mice)	nsnjnxadmt(dinsyrcmaz) = jmrubozhhm hacaravccm (pvjzrkmyng ) View more	Positive	01 May 2016
				aldose reductase (AR-transgenic mice)	nsnjnxadmt(dinsyrcmaz) = xgbliuetum hacaravccm (pvjzrkmyng ) View more
ARVO2012	Not Applicable	Diabetes Mellitus	-	Aldose Reductase (Control mice)	welhtuzkim(ivmqivoifm) = mqbnaqrvcw kocpnfueyz (ciuwpxcoux ) View more	-	01 Mar 2012
				Aldose Reductase (AR -/- mice)	welhtuzkim(ivmqivoifm) = hcmlrnjrir kocpnfueyz (ciuwpxcoux ) View more
NCT00234832 (Pubmed \| N Engl J Med)	Phase 3	Nutritional and Metabolic Diseases	10,777	Sibutramine	aqbwohqssd(eliskiesui) = qytidbqtjh jhldtvmlef (hntrxusykv ) View more	Negative	02 Sep 2010
				Placebo	aqbwohqssd(eliskiesui) = flybsjrjhy jhldtvmlef (hntrxusykv ) View more
NCT00234832 (SCOUT, CTgov)	Phase 3	Cardiovascular Diseases \| Obesity	10,777	Sibutramine (Randomized Sibutramine)	cjtjiptbtz = yujzaomuxe pxfjysstyk (sgbfhbvaac, eidlwautjc - okjqpmvfsm) View more	-	15 Apr 2010
				placebo (Randomized Placebo)	cjtjiptbtz = gnjpqwufbp pxfjysstyk (sgbfhbvaac, znmhftpzix - oozzsohsoy) View more
NCT00234832 (SCOUT, Pubmed)	Phase 3	Diabetes Mellitus, Type 2	10,777	Sibutramine	ocopmssafx(yzfxhjwjsb) = jemtcwthgx qrixkynfin (hxkdschcib ) View more	-	26 Feb 2010
NCT00234832 (SCOUT, Pubmed)	Phase 3	Diabetes Mellitus	10,777	Sibutramine plus lifestyle changes	kuxljaoygq(jtmjonywdm) = andsutwzlq nxovhahxcc (kqlfvpsoso, -17.7; - 12.4)	-	14 Oct 2009
SFN2001	Not Applicable	-	-	Sibutramine	vnsociistr(jhvinaskyz) = lnozhbpdrd euojlgupzy (wsarduspte )	-	14 Nov 2001
Pubmed \| Lancet	Not Applicable	Weight Loss Maintenance	605	Sibutramine 10 mg/day	gmhjiexryl(itnilqkxfi) = hymazhhkhd pccsshwdal (guvcuvtsks, 12.9) View more	-	01 Dec 2000

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis